Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals, Human Genetic Therapies, and Regenerative Medicine. The Specialty Pharmaceuticals segment offers products for the treatment of attention deficit and hyperactivity disorder, including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor; EQUASYM; and ADDERALL XR. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of active ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist that stimulates gastrointestinal motility. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts, as well as for the treatment of thrombocythemia. The Human Genetic Therapies segment offers REPLAGAL for Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for hereditary angioedema. The Regenerative Medicine segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of attention deficit hyperactivity disorder, gastrointestinal diseases, human genetic therapies, and regenerative medicine areas, as well as in other therapeutic areas. The company markets its products through distributors in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.